Georgios Gakis1, Peter C Black2, Bernard H Bochner3, Stephen A Boorjian4, Arnulf Stenzl5, George N Thalmann6, Wassim Kassouf7. 1. Department of Urology, Eberhard-Karls University of Tübingen, Germany. Electronic address: georgios.gakis@med.uni-tuebingen.de. 2. Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. 3. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Urology, Mayo Clinic, Rochester, MN, USA. 5. Department of Urology, Eberhard-Karls University of Tübingen, Germany. 6. Department of Urology, Inselspital Bern, University of Bern, Switzerland. 7. Division of Urology, McGill University, Montreal, QC, Canada.
Abstract
CONTEXT: Urothelial carcinoma is considered a pan-urothelial disease. As such, the remnant urothelium in the upper urinary tract and urethra following radical cystectomy (RC) remains at risk for secondary urothelial tumors (SUTs). OBJECTIVE: To describe the incidence, diagnosis, treatment, and outcomes of patients with SUTs after RC. EVIDENCE ACQUISITION: A systematic search was conducted using PubMed database according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2016 reporting on malignant diseases of the urothelium after RC for bladder cancer. The search strategy separated between upper and lower tract urothelial tumors. EVIDENCE SYNTHESIS: Of a total of 1069 studies, 57 were considered for evidence synthesis. SUTs occured in approximately 4-10% of patients after RC. Carcinoma in situ of the bladder, a history of nonmuscle invasive bladder cancer, and tumor involvement of the distal ureter are the strongest risk factors for secondary upper tract tumors. Risk factors for secondary urethral tumors represent urothelial malignancy in the prostatic urethra/prostate and bladder neck (in women), nonorthotopic diversions, and positive findings on permanent sections. The majority of patients (84%) with SUTs, presented with urothelial recurrence without evidence of metastasis. Of those, 84.0% were treated with surgery, 10.5% with systemic chemotherapy and/or radiotherapy, and 5.6% with topical chemotherapy and/or immunotherapy. After a median follow-up of 91 mo (range: 26-155), 65.9% of patients died of disease and 21.5% died of other causes. Detection and treatment of SUTs at an asymptomatic stage can reduce the risks of cancer-specfific and overall mortality by 30%. A limitation of the study is that the available data were retrospective. CONCLUSIONS: SUTs are rare oncological events and most patients have an adverse prognosis despite absence of distant disease at diagnosis. Therefore, surveillance of the remnant urothelium should be implemented for patients with histological features of panurothelial disease as it may improve timely detection and treatment. PATIENT SUMMARY: Secondary tumors of the renal pelvis, ureters, and urethra occur in approximately 4-10% of patients after radical removal of the bladder for bladder cancer. These patients' prognoses are reduced, likely due to delayed diagnosis. Therefore, routine surveillance might be important to detect tumors at an early stage.
CONTEXT: Urothelial carcinoma is considered a pan-urothelial disease. As such, the remnant urothelium in the upper urinary tract and urethra following radical cystectomy (RC) remains at risk for secondary urothelial tumors (SUTs). OBJECTIVE: To describe the incidence, diagnosis, treatment, and outcomes of patients with SUTs after RC. EVIDENCE ACQUISITION: A systematic search was conducted using PubMed database according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2016 reporting on malignant diseases of the urothelium after RC for bladder cancer. The search strategy separated between upper and lower tract urothelial tumors. EVIDENCE SYNTHESIS: Of a total of 1069 studies, 57 were considered for evidence synthesis. SUTs occured in approximately 4-10% of patients after RC. Carcinoma in situ of the bladder, a history of nonmuscle invasive bladder cancer, and tumor involvement of the distal ureter are the strongest risk factors for secondary upper tract tumors. Risk factors for secondary urethral tumors represent urothelial malignancy in the prostatic urethra/prostate and bladder neck (in women), nonorthotopic diversions, and positive findings on permanent sections. The majority of patients (84%) with SUTs, presented with urothelial recurrence without evidence of metastasis. Of those, 84.0% were treated with surgery, 10.5% with systemic chemotherapy and/or radiotherapy, and 5.6% with topical chemotherapy and/or immunotherapy. After a median follow-up of 91 mo (range: 26-155), 65.9% of patients died of disease and 21.5% died of other causes. Detection and treatment of SUTs at an asymptomatic stage can reduce the risks of cancer-specfific and overall mortality by 30%. A limitation of the study is that the available data were retrospective. CONCLUSIONS:SUTs are rare oncological events and most patients have an adverse prognosis despite absence of distant disease at diagnosis. Therefore, surveillance of the remnant urothelium should be implemented for patients with histological features of panurothelial disease as it may improve timely detection and treatment. PATIENT SUMMARY: Secondary tumors of the renal pelvis, ureters, and urethra occur in approximately 4-10% of patients after radical removal of the bladder for bladder cancer. These patients' prognoses are reduced, likely due to delayed diagnosis. Therefore, routine surveillance might be important to detect tumors at an early stage.
Authors: Ofer Yossepowitch; Guido Dalbagni; Dragan Golijanin; S Machele Donat; Bernard H Bochner; Harry W Herr; William R Fair; Paul Russo Journal: J Urol Date: 2003-01 Impact factor: 7.450
Authors: Ganesh V Raj; Raanan Tal; Andrew Vickers; Bernard H Bochner; Angel Serio; S Machele Donat; Harry Herr; Semra Olgac; Guido Dalbagni Journal: Cancer Date: 2006-11-01 Impact factor: 6.860
Authors: Stefan Denzinger; Kristin Mohren; Ruth Knuechel; Peter J Wild; Maximilian Burger; Wolf F Wieland; Arndt Hartmann; Robert Stoehr Journal: Hum Pathol Date: 2005-12-15 Impact factor: 3.466
Authors: Martin C Schumacher; Michael Scholz; Erik S Weise; Achim Fleischmann; George N Thalmann; Urs E Studer Journal: J Urol Date: 2006-12 Impact factor: 7.450
Authors: Peter E Clark; John P Stein; Susan G Groshen; Gus Miranda; Jie Cai; Gary Lieskovsky; Donald G Skinner Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: Thomas Akkad; Christian Gozzi; Martina Deibl; Tilko Müller; Alexandre E Pelzer; Germar M Pinggera; Georg Bartsch; Hannes Steiner Journal: J Urol Date: 2006-04 Impact factor: 7.450
Authors: Markus Renninger; Omar Fahmy; Tina Schubert; Manuel Alexander Schmid; Fahmy Hassan; Arnulf Stenzl; Georgios Gakis Journal: World J Urol Date: 2019-04-27 Impact factor: 4.226
Authors: Gianpaolo P Carpinito; Grayden S Cook; Aaron N Tverye; Samuel A Gold; Yair Lotan; Vitaly Margulis; Jeffrey M Howard Journal: Can Urol Assoc J Date: 2022-07 Impact factor: 2.052